Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials.
articipants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks.
Eliminating amyloid from the brain may prevent symptoms in those who are destined to acquire early-onset Alzheimer’s disease, according to a clinical experiment. This suggests the need for additional research.
In addition to being the first to examine the safety and effectiveness of an automated insulin delivery (AID) system in conjunction with an Abbott FreeStyle Libre® 2 family sensor
Mounjaro, the First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes.
New active components, such as antibodies, are often evaluated separately in laboratory animals. Researchers at UZH have now created a method that can test up to 25 antibodies in a single mouse. This could not only accelerate the research and development pipeline for new pharmaceuticals, but also significantly reduce the number of experimental animals needed.
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
The researchers created a highly effective conversion technique using mouse cells that can generate over ten neurons from a single skin cell.
The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
